An inspiring play about Parkinson’s and Parkour is coming to a theatre near you
Author: Geoffrey ChangPublished: 8 September 2016
Prep: Cook: Serves:
A new thought-provoking play that explores the friendship between a free-running teenager and a woman with early-onset Parkinson’s is going on a nationwide tour
After three sell-out shows in cities across the UK and rave reviews, a new Parkinson’s play called Kinetics is taking to the road for a run of 13 performances throughout September and October.
Based on a true story, the inspiring theatre piece explores the unlikely friendship between a teenage boy who is devoted to free running (Parkour) – the extreme sport that involves navigating obstacles without equipment – and a middle-aged woman with early-onset Parkinson’s disease.
But what can they possibly have in common? Despite living completely opposing lives, a chance encounter leads the two protagonists to realise the answer: they share the desire to move.
Featuring projected imagery and electrifying live Parkour, the show raises awareness of Parkinson’s with wit, while challenging perceptions and giving a realistic insight into the daily struggles that come with living with the condition.
Written by actor and drama teacher, Sue Wylie, the play recounts her personal experience of living with Parkinson’s. Sue, who performs the lead role, explains: “Five years ago shortly after my 50th birthday I was diagnosed with Parkinson’s. After the initial shock I knew I wanted to write about it. I was teaching drama at the time and discovered that a bright but rebellious 16-year-old student in my tutor group was free running on the school roof.
“I was intrigued by the risks he took in his addiction to this extreme sport. How interesting to contrast that with a middle-aged woman whose world of movement is slowly being eroded. What if their paths should accidentally cross and a friendship form? I knew there was a story in there and so Kinetics was born.”
Sue Wylie (left) playing lead character Rose
Through the juxtaposition of the characters the sharp script, full of emotion and humour, unexpectedly draws parallels between two lives that couldn’t seem more opposite. The two learn more important life lessons from one another than they ever could have imagined.
Following the initial success of sold out shows last year, Kinetics received funding from the Arts Council, allowing them to organise the upcoming Autumn 2016 tour. Parkinson’s UK have officially endorsed the play with CEO Steve Ford saying: “Sue’s play offers an inspiring story to which we can all relate.”
Practical advice on making oral medication easier to swallow
7 days ago
Pig cells implanted into human brain as Parkinson’s treatment
A new treatment, which involves the implantation of pig cells into a human brain, is being tested as a potential treatment for Parkinson’s. The therapy, called NTCELL, has been developed by New Zealand-based biotechnology company Living Cell Technologies, and produces factors that promote central nerve system growth and repair nerve degeneration. Although still in the early stages of testing, the results have been promising with those being treated showing an improvement over an 18-month period. Roger Barker, professor of Clinical Neurosciences at the University of Cambridge, said: “The strategy is a good idea. The question is how competitive that will be compared with other cell therapies.” The treatment could be available as early as 2018.
Fruit flies help shed light on development of Parkinson’s disease
A study carried out by medical students from Juntendo University in Tokyo, Japan, has found that a loss of mitochondrial protein can exacerbate the progression of Parkinson’s disease. The research centred on the study of mutant fruit flies. The team examined what happened to the flies that lacked mitochondrial protein CHCHD2 – a protein that plays a key role in maintaining the structure of cells. The study found that the lack of CHCHD2 led to motor dysfunctions, such as the loss of climbing ability, as the flies aged. However, when researchers introduced a form of human CHCHD2 to the flies, the dysfunctions were reversed. The researchers, led by medical students Hongrui Meng and Chikara Yamashita, said their results shed light on the role of CHCHD2 mutations in Parkinson’s and offer “potential therapeutic targets in Parkinson’s caused by mitochondrial dysfunction.”
3 weeks ago
New research suggests sleep disorders could be early sign of Parkinson’s
New research has found that sleep disorders could be an early warning sign for Parkinson’s. The study, carried out by the University of Toronto, found that 80% of those suffering from rapid eye movement (REM) sleep disorders during dreaming went on to develop neurological conditions. Dr John Peever, who led the study, said: “Our research suggests sleep disorders may be an early warning sign for diseases that may appear some 15 years later in life.” “We observed that more than 80% of people who suffer from REM sleep disorder eventually develop synucleinopathies, such as Parkinson’s disease.” Dr Peever hopes that these findings will help combat neurological conditions in the future. “Much like we see in people prone to cancer, diagnosing REM disorders may allow us to provide individuals with preventative actions to keep them healthy long before they develop these more serious neurological conditions,” Dr Peever continued.